DioTree is passionately dedicated to developing innovative treatment for high grade serous ovarian cancer (HGSOC), one of the deadliest human cancers with an extremely poor prognosis. Our groundbreaking approach involves the development of a first-of-its-kind small molecule technology designed to target and inhibit the enzyme DIO3, which drives ovarian cancer progression. We are committed to advancing the frontiers of cancer treatment and making a positive impact on the lives of those affected by this devastating disease.
Dr. Sarit Batsir
Dr. Sarit Batsir, our CEO, holds a Ph.D. in life science from the Weizmann Institute of Science and has over 8 years of experience in the healthcare industry. Her expertise spans across clinical trials, medical regulations, business development, licensing, and legal aspects. With her leadership and industry knowledge, Sarit is integral to our mission to develop innovative solutions to combat high grade serous ovarian cancer (HGSOC) and improve patient outcomes.
Prof. Osnat Ashur-Fabian
As the founder and CSO of DioTree, Prof. Osnat Ashur-Fabian brings a wealth of experience to our team. With a Ph.D. from the Sackler Faculty of Medicine at Tel-Aviv University, Osnat is currently an Associate Professor at the same institution. She also serves as the Director of Translational Oncology Research at Meir Medical Center, with over 20 years of experience in cancer research. Osnat is the inventor of several patents and has vast experience in commercializing new cancer treatments. Her innovative mindset and extensive knowledge are invaluable in leading our team's efforts to develop novel small molecule technology to combat high grade serous ovarian cancer (HGSOC) and improve patient outcomes.
Dr. Dotan Moskovich
Head of R&D
Dotan Moskovich, Ph.D at the Translational Oncology Research Laboratory at Meir Medical Center, affiliated to the Sackler Faculty of Medicine, Tel-Aviv University. Under the supervision of Prof. Ashur-Fabian, Dotan accumulated vast expertise both in basic and translational oncological research, focusing on ovarian cancer.
BOARD OF DIRECTORS
This is your Team section. Briefly introduce the team then add their bios below. Click here to edit.
Our company's innovative technology involves a series of small molecules that specifically target the DIO3 enzyme, which is highly expressed in various aggressive cancers, including high grade serous ovarian cancer (HGSOC). DIO3 is involved in tumor growth and is an attractive target for inhibition. Our team is the first to generate a series of novel small molecules for DIO3 inhibition, and we are proud to have been granted patent protection in the US and Europe (EP3119768B1; US10435365B2).
Here are some of our key findings:
We have established that ovarian cancer is DIO3-dependent in both cells and mice models.
Using the 'best hit' DIO3 inhibitors, we have achieved high efficacy in both ovarian cancer cells and mice models.
We have confirmed a high safety profile through toxicology experiments.
With these exciting results, we are confident that our technology has the potential to make a significant impact in the fight against cancer
Ovarian cancer is a particularly deadly form of cancer, with a five-year survival rate of only 30%. It is the fifth leading cause of cancer-related deaths among women, and an estimated 313,959 new cases and 207,252 deaths were reported worldwide in 2020. High grade serous ovarian cancer (HGSOC), in particular, is among the deadliest human cancers and accounts for 70% of all ovarian cancer cases.